权益分类	功能权益	普通用户	{{item.name}}会员
{{category.name}}	{{benefitItem.name}}

Genetic and Signaling Pathways in Epithelial Thyroid Cancer

上皮性甲状腺癌的遗传和信号通路

基本信息

批准号：
8657014
负责人：
Matthew D Ringel
金额：
$ 217.65万
依托单位：
OHIO STATE UNIVERSITY
依托单位国家：
美国
项目类别：
财政年份：
2008
资助国家：
美国
起止时间：
2008-03-01 至 2018-03-31
项目状态：
已结题

来源：
https://reporter.nih.gov/project-details/8657014
关键词：
12q14 4q32 8q24 Address Area BRAF gene Behavior Biological Assay Cancer Family Cancer Model Candidate Disease Gene Cells Clinical Clinical Trials Data Development Diagnosis Disease Disease Progression Early Diagnosis Enhancers Epithelial Event Family Follicular thyroid carcinoma Genes Genetic Genetic Models Genomics Goals Imaging Techniques In Vitro Incidence Individual Indolent Iodine MEKs Malignant Neoplasms Malignant neoplasm of thyroid Mediating Methods Mitochondria Modeling Molecular Genetics Molecular Target Mus Neoplasm Metastasis Neoplasms Oncogenes Outcome PTEN gene Papillary thyroid carcinoma Pathogenesis Pathway interactions Patients Play Population Predisposition Primary Neoplasm Process Regulation Research Resistance Risk Risk Assessment Role Signal Pathway Signal Transduction Susceptibility Gene Testing Therapeutic Thyroid Gland Tissues Toxic effect Translating United States Variant Woman Work base cancer cell cancer genetics cancer risk cell motility clinical care clinical practice design effective therapy genetic linkage analysis genetic variant improved in vivo inhibitor/antagonist kinase inhibitor kindred member men model design mouse model new technology new therapeutic target novel p21 activated kinase positional cloning small molecule tumor tumor progression tumorigenesis uptake

项目摘要

DESCRIPTION (provided by applicant): The primary goal of this P01 is to improve the outcomes and lives of patients with thyroid cancer by identifying genetically "at-risk" individuals allowing for early diagnosis and prediction of tumor behavior, new pathways that influence cancer development and progression, and improving outcomes of patients with metastatic disease by improving existing therapies or validating new treatment targets. Several factors support the importance of applying these efforts to thyroid cancer: (1) Thyroid cancer incidence is rising at the fastest rate of all malignancies in the United States. (2) Thyroid cancer typicall takes an indolent course when patients are diagnosed early, thus with the increasing incidence there is an ever enlarging population of individuals surviving long-term. (3) For patients with more aggressive forms of thyroid cancer, current treatment options need to be improved or replaced with more effective treatments. Over the course of the first cycle of this P01 our group has together worked toward these goals and made key observations with potential to impact on patients with differentiated thyroid cancer (papillary and follicular). The goal for this competing renewal is to extend the work on the most promising findings that have greatest likelihood to be translated into practice or that represent key advances in the field with potential to alter paradigms used in research or clinical practice. Specifically, we will functionally characterize genes that predispose to PTC in families identified in the first cycle of the P01 and apply new technologies to a larger number of informative families to identify more potential genes that predispose to PTC (Project 1), extend the work using a candidate gene approach for FTC and PTC risk that has identified interactions between signaling pathways (Project 2); design approaches to enhance 1-131 therapy using novel mouse imaging techniques developed in the P01 and extend that work to identify other unknown regulators of this process (Project 3); and fully determine the role and potential therapeutic importance of p21 activated kinase (PAK), a newly identified signaling pathway downstream of BRAF, in thyroid cancer in vivo, and determine its role in resistance to RAF inhibitors (Project 4).

描述（由申请人提供）：本P01的主要目标是通过识别基因“高危”个体来改善甲状腺癌患者的预后和生活